ScholarLens Back to search
2020•Frontiers in Cell and Developmental BiologyOpen access

GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds

Kathrin Brockmann

Open full text 13 citations

Abstract

As we are now entering the era where disease-modifying treatment options such as alpha-synuclein targeting compounds are tested in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies are a much-needed prerequisite to introduce patients to specific therapies. Such a scenario will be exemplified for GBA, one major genetic risk factor that is specifically associated with the alpha-synucleinopathies Parkinson’s Disease and Dementia with Lewy Bodies.

Open-access reader

About this research paper

What this paper is about

As we are now entering the era where disease-modifying treatment options such as alpha-synuclein targeting compounds are tested in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies are a much-needed prerequisite to introduce patients to specific therapies. Such a scenario will be exemplified for GBA, one major genetic risk factor that is specifically associated with the alpha-synucleinopathies Parkinson’s Disease and Dementia with Lewy Bodies.

Why it matters

OpenAlex reports 13 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

As we are now entering the era where disease-modifying treatment options such as alpha-synuclein targeting compounds are tested in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies are a much-needed prerequisite to introduce patients to specific therapies. Such a scenario will be exemplified for GBA, one major genetic risk factor that is specifically associated with the alpha-synucleinopathies Parkinson’s Disease and Dementia with Lewy Bodies.

Key concepts: Synucleinopathies, Alpha-synuclein, Dementia with Lewy bodies, Parkinson's disease, Neuroscience, Disease, Dementia, Medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds — Research Paper | ScholarLens